Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Goyang-si
Clinical trial register · South Korea

Clinical Trials in Goyang-si, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 111 Goyang-si 29 Daegu 20 Suwon 19 Seongnam 16
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca72 Merck Sharp & Dohme LLC29 National Cancer Center, Korea23 Janssen Research & Development, LLC20 Hoffmann-La Roche19 Clear sponsor filter
Site location
Seoul111 Goyang-si29 Daegu20 Suwon19 Seongnam16
All 46 locations
Target enrolment
to

Trials with a site in Goyang-si

29 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Goyang-si, Suwon, Cheongju-si, Daegu, Seoul
2026-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Goyang-si, Seongnam-si, Suwon, Cheongju-si, Seoul
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
60
Goyang-si, Seoul
2026-03-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Goyang-si, Suwon, Daegu, Seoul
2026-03-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Goyang-si, Jongno-gu, Seodaemun-Gu, Seoul
2026-01-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2
180
Goyang-si, Seongnam-si, Cheongju-si, Seoul
2025-12-12
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
298
Goyang-si, Seoul
2025-07-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Goyang-si, Seongnam-si, Suwon, Gangnam, Songpa-gu, Buk-Gu, Seoul
2025-07-16
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Goyang-si, Kyonggi-do, Taegu, Seoul
2025-06-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Goyang-si, Seodaemun-Gu, Songpa-gu, Seoul
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Goyang-si, Seongnam, Daegu, Seoul
2025-03-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Goyang-si, Busan, Daejeon, Seoul
2025-01-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Goyang-si, Suwon, Seoul
2024-10-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Goyang-si, Seongnam, Suwon, Pusan, Cheongju-si, Busan, Daegu, Junggu
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Goyang-si, Seongnam, Suwon, Cheongju-si, Daegu, Seoul
2024-04-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Goyang-si, Seongnam, Buk-gu, Pusan, Seoul
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Wŏnju, Goyang-si, Suwon, Cheongju-si, Daegu, Seoul
2023-12-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Goyang-si, Seongnam, Suwon, Cheongju-si, Daegu, Seoul
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hwasun, Goyang-si, Seongnam, Suwon, Yangsan, Cheongju-si, Busan, Junggu
2023-11-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Goyang-si, Seongnam, Songpagu, Seoul
2022-03-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Goyang-si, Seongnam, Seoul
2021-06-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Goyang-si, Daejeon, Seoul
2021-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Goyang-si, Seongnam-si, Seoul
2021-01-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Goyang-si, Seongnam-si, Suwon, Busan, Songpagu, Daegu, Seoul
2020-12-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Goyang-si, Seongnam-si, Suwon, Jinju, Cheongju-si, Daegu, Seoul
2020-07-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Goyang-si, Seongnam-si, Songpagu, Deagu, Seoul
2019-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Goyang-si, Seoul
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Hwasun Gun, Goyang-si, Seongnam-si, Suwon, Seoul
2018-12-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Inceon, Hwasun, Goyang-si, Seongnam-si, Suwon, Cheongju-si, Gangnam-gu, Songpagu
2018-08-21
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/goyang-si

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies with a site in Goyang-si that also match the filters currently applied.

How many clinical trials are recruiting in Goyang-si?

17 of the 29 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Goyang-si), 29 studies
PhaseStudiesRecruitingShare
Phase 3261489.7%
Phase 1/2226.9%
Phase 2113.4%

Most active sponsors

Lead sponsors with the most studies (Goyang-si)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC2917
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.